Masimo (NSDQ:MASI) said today it won FDA clearance for its NomoLine capnography sampling lines.
The newly cleared NomoLine sampling lines are compatible with both Masimo and third-party OEM NomoLine monitors to allow for sidestream capnography and gas monitoring the Irvine, Calif.-based company said. The lines are designed for both intubated and non-intubated patients in low and high humidity applications.
Masimo touted that the NomoLine sampling lines feature no-moisture sampling technology designed to eliminate issues associated with conventional sidestream gas sampling line systems. The NomoLines feature the company’s patented polymer and allow water in sampling lines to continuously evaporate into the surrounding air and leave oxygen, carbon dioxide and anesthetic gases unaffected.
“With NomoLine, we’ve developed innovative moisture-wicking technology – and then applied that breakthrough to an entire line of cannulas, including neonatal airway adapter sets. Masimo continues to automate noninvasive monitoring with solutions such as NomoLine that are reliable and easy to use,” founder & CEO Joe Kiani said in a press release.
Earlier this month, Masimo reported third-quarter results that crushed the consensus earnings forecast and raised its sales and earnings outlook for the rest of the year.